United States: The SEC's Insider Trading Case Against a Clinical Trial Physician: Lessons For Physicians, Investors, and Public Companies

Originally published November 15, 2010

On November 2, 2010, the Securities and Exchange Commission ("SEC") brought an action for insider trading against a physician involved in an investigational drug clinical trial based on the alleged use of confidential information about the clinical trial disclosed by the physician to a hedge fund portfolio manager. The U. S. Department of Justice ("DOJ") also initiated parallel criminal proceedings for securities fraud based on the same allegations. The charges by the agencies reflect a more aggressive response by the SEC and other federal law enforcement agencies to alleged acts of insider trading as well as a new focus on the growing number of medical professionals that act as consultants to Wall Street investors. As a result, if the SEC and DOJ are successful, the case could have significant implications for: (1) hedge fund managers and other investors working with consultants from the medical community; (2) pharmaceutical and medical device manufacturers testing new products in clinical trials; and (3) physicians and other third parties involved in the conduct of clinical trials. Even if the SEC and DOJ are not ultimately successful, the existence of the case warrants a reconsideration of relationships among investors, manufacturers and third parties involved in clinical trials.

Summary of the Charge and Supporting Allegations

A French physician, Yves M. Benhamou, M.D., was charged with unlawfully providing confidential information regarding disappointing clinical trial results to a hedge-fund portfolio manager. The charge is based on allegations related to the physician's involvement as a consultant and lead investigator for clinical trials conducted by Human Genome Science, Inc. ("HGSI"). The clinical trials involved a new drug then known as Albuferon that HGSI was developing for the treatment of chronic hepatitis C. According to the allegations, Dr. Benhamou was a member of a five person steering committee overseeing the Albuferon clinical trial. The physician was also the "country lead investigator" for France and other parts of Europe. While acting in these capacities, Dr. Benhamou was also retained as a consultant by a portfolio manager, who was managing portfolios of health care hedge funds that, during the relevant period, were collectively long approximately six million shares of HGSI. Dr. Benhamou allegedly alerted the portfolio manager about a setback in the clinical trial. This "tip" occurred several days before HGSI's public announcement of the issues with the trial. In response to the tip, the hedge funds allegedly sold their HGSI positions, avoiding nearly $30 million in losses.

The Case Against the Physician

To prove its insider trading case, the government will need to establish that the physician provided the portfolio manager with material, nonpublic information in breach of a duty of trust or confidence. There are potential issues with the allegations supporting the case. As a preliminary matter, there are questions regarding the confidential nature of the information. First, the SEC suggests that the information was discussed in meetings involving members of the committee charged with monitoring, the clinical trial, steering committee members, HGSI representatives and unidentified others. If attendance included individuals not subject to confidentiality agreements, the information may no longer have been confidential as a result of those meetings.

Second, the government does not clearly define the duty of trust or confidence that Dr. Benhamou owed HGSI's shareholders. The SEC complaint offers alternative theories on the origins of Dr. Benhamou's alleged duty, stating that the duty is both , arising [b]y virtue of his role in the clinical trial, and , "in accordance with the terms of his contract with HGSI."1With respect to the physician's contractual obligations, an affidavit filed in support of the criminal complaint states that the physician signed an agreement in July 2004, years before the events in question, in which he agreed to preserve the confidentiality of any confidential information he received from HGSI. Curiously, two days after HGSI announced the problems encountered in the clinical trial, and after HGSI's stock price declined by approximately 40%, HGSI asked the physician to sign another agreement in which the physician agreed to act as a consultant to HGSI and to preserve the confidentiality of any information received from HGSI. However, according to the affidavit, in a 2009 interview with the government, the physician stated that he always considered himself bound to preserve the confidentiality of all information received from HGSI. If this case is litigated, there will likely be a dispute over whether the physician was in fact contractually obligated to preserve the confidentiality of information he received relating to the clinical trial. If the contractual obligations are deemed insufficient to support insider trading charges, the physician's status on the steering committee will need to be evaluated to determine whether this role imposed a confidentiality obligation on the physician.

While there may be potential issues with the specific allegations in this case, the case nonetheless highlights an overlooked legal risk for physicians and other third parties involved in clinical trials who have access to confidential information. Most notably, physicians and other medical professionals similarly situated to Dr. Benhamou who serve multiple professional roles should be aware of what information may be used when serving as Wall Street consultants and what information should be kept confidential to avoid insider trading liability. To minimize insider trading risk, other third parties involved in clinical trials may want to review their policies and procedures for communicating to personnel, and enforcing compliance with, confidentiality provisions in agreements with manufacturers conducting clinical trials. In particular, if a clinical site contracts with a manufacturer on behalf of an investigator, the site may want specific assurances from the investigator that confidentiality obligations will be satisfied. In the wake of the Dr. Benhamou case, third parties should also be ready to respond to requests from manufacturers for enhanced confidentiality protections and know what they can reasonably accept.

Possible Claims Against the Hedge Funds and Their Advisors

No charges have been filed to date against the hedge funds that allegedly traded based on the physician's tip, the investment advisers to those funds, or the portfolio manager that received the alleged tip. However, the SEC complaint states that the portfolio manager knew or should have known that the doctor was providing him with information in breach of a confidentiality obligation. According to the SEC complaint, the portfolio manager knew or should have known of the breach even though the doctor agreed not to provide the portfolio manager with confidential information. The manager's awareness of the doctor's breach is allegedly based upon his awareness that the doctor "served on the trial's Steering Committee and owed a duty of confidentiality to HGSI."2

A 2005 study found that nearly 1 out of 10 U.S. physicians was engaged in some consultancy with the investment industry.3

Possible Regulation FD Issues

Members of the investment community that hire such consultants need to be aware that their retained industry experts could be basing their opinions on confidential information and that simply having a contractual clause with the consultant requiring them not to pass along confidential information may not be enough to escape insider trading liability. This risk is particularly acute when the consultant is in a close relationship to the issuer, including current or former employees of the issuer. Hedge fund advisers and other professional investors may want to consider adopting or reviewing policies regarding the use of industry consultants. Such policies may require, among other things, that portfolio managers and other investment personnel remind consultants of their obligation not to pass along confidential information at the outset of each contact, and that compliance staff monitor conversations between investment personnel and consultants.

No allegations have been filed against HGSI, nor does either of the government's complaints allege any wrongdoing by HGSI. However, it is of interest that HGSI asked the physician to sign a new confidentiality agreement two days after the announcement of the problems encountered in the clinical trial. This may have occurred because of concerns about Regulation FD, which provides that "[w]henever an issuer, or any person acting on its behalf, discloses any material nonpublic information regarding that issuer or its securities to...[an investor]..., the issuer shall make public disclosure of that information...[s]imultaneously, in the case of an intentional disclosure...and [p]romptly, in the case of a non-intentional disclosure."4

As a more general matter, for manufacturers conducting clinical trials, the case highlights the potential need to enhance protection of the confidential information available to the broad range of third parties who assist in the conduct of clinical trials. Manufacturers should catalogue the third parties with likely access to clinical trial information during the course of the clinical trial (e.g., scientific advisors, investigators, clinical sites, independent review board members, data monitoring committee members, clinical research organizations, biostatisticians) and ensure that agreements with each of those third parties have confidentiality provisions or that third parties are otherwise put on notice about the need to preserve confidentiality. Manufacturers may also want to review their standard confidentiality provisions in clinical trial agreements and consider whether those provisions could be strengthened. For example, manufacturers may want to include: (1) an acknowledgement that the other parties (or their directors, officers, employees and agents) involved in the conduct of the clinical trial may be "insiders" who have gained material, nonpublic information about the clinical trial as a result of that involvement; and (2) an agreement by the other parties not to engage in transactions, or advise others to engage in transactions, involving manufacturer stock until the clinical trial results are public. As another example, manufacturers may want to include specific provisions ensuring that any employees, contractors or other agents used by the third parties are subject to, and aware of, the particular confidentiality obligations contained in the agreement. In addition, manufacturers may want to consider specifically requiring third parties involved in clinical trials to disclose any relationships with members of the financial industry to the manufacturer as part of the contracting process and ensure that confidentiality obligations are discussed in investigator meetings.


1. SEC Compl. ¶ 8.

2. SEC Compl. ¶ 3.

3. Topol & Blumental, "Physicians and the Investment Industry," Journal of the American Medical Association, June 1, 2005.

4. 17 C.F.R. § 243.100(a)(1-2) (2010).


The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on Mondaq.com.

Click to Login as an existing user or Register so you can print this article.

In association with
Related Video
Up-coming Events Search
Font Size:
Mondaq on Twitter
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
Email Address
Company Name
Confirm Password
Mondaq Topics -- Select your Interests
 Law Performance
 Law Practice
 Media & IT
 Real Estate
 Wealth Mgt
Asia Pacific
European Union
Latin America
Middle East
United States
Worldwide Updates
Check to state you have read and
agree to our Terms and Conditions

Terms & Conditions and Privacy Statement

Mondaq.com (the Website) is owned and managed by Mondaq Ltd and as a user you are granted a non-exclusive, revocable license to access the Website under its terms and conditions of use. Your use of the Website constitutes your agreement to the following terms and conditions of use. Mondaq Ltd may terminate your use of the Website if you are in breach of these terms and conditions or if Mondaq Ltd decides to terminate your license of use for whatever reason.

Use of www.mondaq.com

You may use the Website but are required to register as a user if you wish to read the full text of the content and articles available (the Content). You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these terms & conditions or with the prior written consent of Mondaq Ltd. You may not use electronic or other means to extract details or information about Mondaq.com’s content, users or contributors in order to offer them any services or products which compete directly or indirectly with Mondaq Ltd’s services and products.


Mondaq Ltd and/or its respective suppliers make no representations about the suitability of the information contained in the documents and related graphics published on this server for any purpose. All such documents and related graphics are provided "as is" without warranty of any kind. Mondaq Ltd and/or its respective suppliers hereby disclaim all warranties and conditions with regard to this information, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. In no event shall Mondaq Ltd and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use or performance of information available from this server.

The documents and related graphics published on this server could include technical inaccuracies or typographical errors. Changes are periodically added to the information herein. Mondaq Ltd and/or its respective suppliers may make improvements and/or changes in the product(s) and/or the program(s) described herein at any time.


Mondaq Ltd requires you to register and provide information that personally identifies you, including what sort of information you are interested in, for three primary purposes:

  • To allow you to personalize the Mondaq websites you are visiting.
  • To enable features such as password reminder, newsletter alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our information providers who provide information free for your use.

Mondaq (and its affiliate sites) do not sell or provide your details to third parties other than information providers. The reason we provide our information providers with this information is so that they can measure the response their articles are receiving and provide you with information about their products and services.

If you do not want us to provide your name and email address you may opt out by clicking here .

If you do not wish to receive any future announcements of products and services offered by Mondaq by clicking here .

Information Collection and Use

We require site users to register with Mondaq (and its affiliate sites) to view the free information on the site. We also collect information from our users at several different points on the websites: this is so that we can customise the sites according to individual usage, provide 'session-aware' functionality, and ensure that content is acquired and developed appropriately. This gives us an overall picture of our user profiles, which in turn shows to our Editorial Contributors the type of person they are reaching by posting articles on Mondaq (and its affiliate sites) – meaning more free content for registered users.

We are only able to provide the material on the Mondaq (and its affiliate sites) site free to site visitors because we can pass on information about the pages that users are viewing and the personal information users provide to us (e.g. email addresses) to reputable contributing firms such as law firms who author those pages. We do not sell or rent information to anyone else other than the authors of those pages, who may change from time to time. Should you wish us not to disclose your details to any of these parties, please tick the box above or tick the box marked "Opt out of Registration Information Disclosure" on the Your Profile page. We and our author organisations may only contact you via email or other means if you allow us to do so. Users can opt out of contact when they register on the site, or send an email to unsubscribe@mondaq.com with “no disclosure” in the subject heading

Mondaq News Alerts

In order to receive Mondaq News Alerts, users have to complete a separate registration form. This is a personalised service where users choose regions and topics of interest and we send it only to those users who have requested it. Users can stop receiving these Alerts by going to the Mondaq News Alerts page and deselecting all interest areas. In the same way users can amend their personal preferences to add or remove subject areas.


A cookie is a small text file written to a user’s hard drive that contains an identifying user number. The cookies do not contain any personal information about users. We use the cookie so users do not have to log in every time they use the service and the cookie will automatically expire if you do not visit the Mondaq website (or its affiliate sites) for 12 months. We also use the cookie to personalise a user's experience of the site (for example to show information specific to a user's region). As the Mondaq sites are fully personalised and cookies are essential to its core technology the site will function unpredictably with browsers that do not support cookies - or where cookies are disabled (in these circumstances we advise you to attempt to locate the information you require elsewhere on the web). However if you are concerned about the presence of a Mondaq cookie on your machine you can also choose to expire the cookie immediately (remove it) by selecting the 'Log Off' menu option as the last thing you do when you use the site.

Some of our business partners may use cookies on our site (for example, advertisers). However, we have no access to or control over these cookies and we are not aware of any at present that do so.

Log Files

We use IP addresses to analyse trends, administer the site, track movement, and gather broad demographic information for aggregate use. IP addresses are not linked to personally identifiable information.


This web site contains links to other sites. Please be aware that Mondaq (or its affiliate sites) are not responsible for the privacy practices of such other sites. We encourage our users to be aware when they leave our site and to read the privacy statements of these third party sites. This privacy statement applies solely to information collected by this Web site.

Surveys & Contests

From time-to-time our site requests information from users via surveys or contests. Participation in these surveys or contests is completely voluntary and the user therefore has a choice whether or not to disclose any information requested. Information requested may include contact information (such as name and delivery address), and demographic information (such as postcode, age level). Contact information will be used to notify the winners and award prizes. Survey information will be used for purposes of monitoring or improving the functionality of the site.


If a user elects to use our referral service for informing a friend about our site, we ask them for the friend’s name and email address. Mondaq stores this information and may contact the friend to invite them to register with Mondaq, but they will not be contacted more than once. The friend may contact Mondaq to request the removal of this information from our database.


This website takes every reasonable precaution to protect our users’ information. When users submit sensitive information via the website, your information is protected using firewalls and other security technology. If you have any questions about the security at our website, you can send an email to webmaster@mondaq.com.

Correcting/Updating Personal Information

If a user’s personally identifiable information changes (such as postcode), or if a user no longer desires our service, we will endeavour to provide a way to correct, update or remove that user’s personal data provided to us. This can usually be done at the “Your Profile” page or by sending an email to EditorialAdvisor@mondaq.com.

Notification of Changes

If we decide to change our Terms & Conditions or Privacy Policy, we will post those changes on our site so our users are always aware of what information we collect, how we use it, and under what circumstances, if any, we disclose it. If at any point we decide to use personally identifiable information in a manner different from that stated at the time it was collected, we will notify users by way of an email. Users will have a choice as to whether or not we use their information in this different manner. We will use information in accordance with the privacy policy under which the information was collected.

How to contact Mondaq

You can contact us with comments or queries at enquiries@mondaq.com.

If for some reason you believe Mondaq Ltd. has not adhered to these principles, please notify us by e-mail at problems@mondaq.com and we will use commercially reasonable efforts to determine and correct the problem promptly.